Why FDA moved the date

The section 582(g)(3) "Assessment of Small Dispensers" is unfinished. FDA must contract an independent consulting company to assess the feasibility of package-level interoperable tracing for small dispensers, publish the final assessment for public comment, and hold a public meeting on it — and those steps were incomplete as 27 November 2026 approached.

The owning company has 25 or fewer full-time employees licensed as pharmacists or qualified as pharmacy technicians.

The nearest date FDA asked for

22 September 2026; FDA encourages completion and permits a designated consultant to respond.

What the exemption covers

The six lettered requirements of FD&C Act §582(g)(1)(A)–(F), PLUS one narrow slice outside §582(g)(1): the §582(d)(4)(A)(ii)(II) and (d)(4)(B)(iii) requirements for dispensers to verify the product identifier of the statutorily designated proportion of suspect or illegitimate product in their possession or control. Every other requirement in §582 — including all other §582(d)(4) verification duties — ran throughout.

What it never covered

Two, plus a limiter that has changed hands. The 582(d)(4) verification duties the letter expressly preserves stay with the dispenser throughout. And on 582(g)(1)(E) — gathering transaction information back to the manufacturer — the "directly transacted" limiter now attaches to the DISPENSER: "If small business dispensers directly transacted the product(s) subject to the request, they may use current methods to respond." On 582(g)(1)(D), recall and investigation responses, the 6 August 2026 letter extends relief to "Small business dispensers and their trading partners" jointly.

582(g)(1)(F), saleable returns. Where the relief for (A)-(D) reads "Small business dispensers and their trading partners", (F) reads "Small business dispensers’ trading partners" — possessive, not conjunctive. The underlying obligation falls on "each person accepting a saleable return".

Dispensers with 26 or more

Ran from 27 November 2024 until 27 November 2025 — already expired

27 November 2023 — §582(k)(1) effectively ended the requirement for trading partners to provide and receive transaction history

Anything to file with FDA

No. Small dispensers and their trading partners who use the exemptions do not need to submit anything to FDA. FDA separately recommends — but does not require — communicating reliance to trading partners.

Whether to wait it out

No — expressly the opposite, in the letter's closing paragraph.

DSCSA small-dispenser exemption, point by point

The relief covers the same six lettered requirements plus the same narrow verification slice it always did, and nothing has to be filed with FDA to rely on it. The headcount date is still ahead of you, so hiring between now and then can move you across the line.

FDA moved this date on 6 August 2026. The exemption now runs to 27 November 2027, as stated on the current FDA exemptions webpage. rather than 27 November 2026, and the headcount that decides who holds the extra year is taken on 27 November 2026 for the exemption described on the current FDA exemptions webpage..

When the exemption ends: 27 November 2027, as stated on the current FDA exemptions webpage.
Why FDA moved the date: The section 582(g)(3) "Assessment of Small Dispensers" is unfinished. FDA must contract an independent consulting company to assess the feasibility of package-level interoperable tracing for small dispensers, publish the final assessment for public comment, and hold a public meeting on it, and those steps were incomplete as 27 November 2026 approached.
Who counts as small: The owning company has 25 or fewer full-time employees licensed as pharmacists or qualified as pharmacy technicians.
When the headcount is taken: 27 November 2026 for the exemption described on the current FDA exemptions webpage.
The nearest date FDA asked for: 22 September 2026; FDA encourages completion and permits a designated consultant to respond.
What the exemption covers: The six lettered requirements of FD&C Act §582(g)(1)(A), (F), PLUS one narrow slice outside §582(g)(1): the §582(d)(4)(A)(ii)(II) and (d)(4)(B)(iii) requirements for dispensers to verify the product identifier of the statutorily designated proportion of suspect or illegitimate product in their possession or control. Every other requirement in §582, including all other §582(d)(4) verification duties, ran throughout.
What it never covered: Two, plus a limiter that has changed hands. The 582(d)(4) verification duties the letter expressly preserves stay with the dispenser throughout. And on 582(g)(1)(E), gathering transaction information back to the manufacturer, the "directly transacted" limiter now attaches to the DISPENSER: "If small business dispensers directly transacted the product(s) subject to the request, they may use current methods to respond." On 582(g)(1)(D), recall and investigation responses, the 6 August 2026 letter extends relief to "Small business dispensers and their trading partners" jointly.
Saleable returns: 582(g)(1)(F), saleable returns. Where the relief for (A)-(D) reads "Small business dispensers and their trading partners", (F) reads "Small business dispensers’ trading partners", possessive, not conjunctive. The underlying obligation falls on "each person accepting a saleable return".
Dispensers with 26 or more: Ran from 27 November 2024 until 27 November 2025, already expired
Transaction history: 27 November 2023, §582(k)(1) effectively ended the requirement for trading partners to provide and receive transaction history
Anything to file with FDA: No. Small dispensers and their trading partners who use the exemptions do not need to submit anything to FDA. FDA separately recommends, but does not require, communicating reliance to trading partners.
Whether to wait it out: No, expressly the opposite, in the letter's closing paragraph.

Every answer above is the value carried in this site’s claim register, re-verified against its primary source on 2026-08-11. Source: FDA, Exemptions under the Drug Supply Chain Security Act.

What the FDA small-dispenser exemption letters actually say, point by point